Impact of replacing or adding pregnancy‐associated plasma protein‐A at 11–13weeks on screening for preterm pre‐eclampsia

• Published in: Ultrasound in obstetrics & gynecology Vol. 60; no. 2; pp. 200 - 206
• Main Authors: Wah, Y M I, Sahota, D S, Chaemsaithong, P, Wong, L, Kwan, A H W, Ting, Y H, Law, K M, Leung, T Y, Poon, L C
• Format: Journal Article
• Language: English
• Published: London Wiley Subscription Services, Inc 01-08-2022
• Subjects: Biomarkers; Blood pressure; Eclampsia; Growth factors; Gynecology; Obstetrics; Placenta growth factor; Preeclampsia; Pregnancy; Proteins; Screening; Secondary analysis; Statistical analysis; Ultrasonic imaging; Uterus
• ISSN: 0960-7692; 1469-0705
• DOI: 10.1002/uog.24918

ObjectiveTo assess whether pregnancy‐associated plasma protein‐A (PAPP‐A) alters or provides equivalent screening performance as placental growth factor (PlGF) when screening for preterm pre‐eclampsia (PE) at 11–13 weeks of gestation.MethodsThis was a secondary analysis of a non‐intervention screening study of 6546 singleton pregnancies that were screened prospectively for preterm PE in the first trimester between December 2016 and June 2018. Patient‐specific risks for preterm PE were estimated by maternal history, mean arterial pressure (MAP), uterine artery pulsatility index (UtA‐PI), PlGF and PAPP‐A. A competing‐risks model with biomarkers expressed as multiples of the median was used. All women and clinicians were blinded to the risk for preterm PE. The performance of screening for preterm PE using PlGF vs PAPP‐A vs both PAPP‐A and PlGF was assessed by comparing areas under the receiver‐operating‐characteristics (AUC) curves. McNemar's test was used to compare detection rate at a fixed false‐positive rate (FPR) of 10%.ResultsPlGF and PAPP‐A were measured in 6546 women, of whom 37 developed preterm PE. The AUC and detection rate at 10% FPR using PlGF in combination with maternal history, MAP and UtA‐PI were 0.854 and 59.46%, respectively. The respective values were 0.813 and 51.35% when replacing PlGF with PAPP‐A and 0.855 and 59.46% when using both PAPP‐A and PlGF. Statistically non‐significant differences were noted in AUC when replacing PlGF with PAPP‐A (ΔAUC, 0.04; P = 0.095) and when using both PAPP‐A and PlGF (ΔAUC, 0.002; P = 0.423). However, on an individual case basis, screening using PlGF in conjunction with maternal history, MAP and UtA‐PI identified three (8.1%) additional pregnancies that developed preterm PE and that were not identified when replacing PlGF with PAPP‐A. Screening using PAPP‐A in addition to maternal history and other biomarkers did not identify any additional pregnancies.ConclusionOn an individual case basis, adoption of a screening strategy that uses PAPP‐A instead of PlGF results in reduced detection of preterm PE, consistent with previous literature. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.